1,084 results on '"Forconi, Francesco"'
Search Results
2. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
3. Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL
4. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
5. The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells
6. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
7. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
8. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
9. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
10. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment
11. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
12. KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.
13. Mutations in the IgG B cell receptor associated with class-switched B cell lymphomas
14. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells
15. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
16. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
17. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
18. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
19. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma
20. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
21. DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity
22. Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia
23. Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications
24. BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
25. The essential microenvironmental role of oligomannoses inserted into the antigen-binding sites of lymphoma cells
26. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
27. PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
28. S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY
29. PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
30. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
31. Development of DNA vaccines against B-cell neoplasms
32. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms
33. BCL2 Inhibition in Refractory Hairy-Cell Leukemia
34. Supplementary methods and Figures from The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
35. Supplementary Figure 1 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
36. Supplementary Table 4 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
37. Supplementary Figure 2 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
38. Supplementary Tables 1-3 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
39. Supplementary Table 6 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
40. Supplementary Table 5 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
41. Supplementary Tables S1-S4 from The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
42. Supplementary Data from Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
43. Data from STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
44. Supplementary Data from Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells
45. Supplementary Table 7 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
46. CCR Translation for this Article from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
47. Supplemetary data from STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
48. Supplementary Data from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
49. Supplementary Tables and Figures from Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients
50. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.